The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.
The company is seeking partnerships that will enable it to offer its software to more users as part of larger, more integrated systems.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
The companies are combining their respective software platforms to provide an end-to-end genomic testing solution for hospital labs.
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The partners plan to launch a service that will provide access to genomic testing, best practices guidelines, and decision support.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.